Dr. Bowden joined Agios as chief medical officer in May 2014. He has more than 18 years of experience in clinical drug development, including the approval of several cancer medicines. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf
™ for patients with BRAF V600E positive melanoma and Tarceva
™ for patients with EGFr activating mutation positive, non-small cell lung cancer. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, Phases I-III at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology, and he serves on the board of directors at miRagen Therapeutics, Ziopharm Oncology and Cedilla Therapeutics.
What is Christopher Bowden's net worth?
The estimated net worth of Christopher Bowden is at least $735,929.99 as of June 17th, 2021. Dr. Bowden owns 17,989 shares of Agios Pharmaceuticals stock worth more than $735,930 as of December 18th. This net worth approximation does not reflect any other investments that Dr. Bowden may own. Learn More about Christopher Bowden's net worth.
How do I contact Christopher Bowden?
Has Christopher Bowden been buying or selling shares of Agios Pharmaceuticals?
Christopher Bowden has not been actively trading shares of Agios Pharmaceuticals during the last quarter. Most recently, Christopher Bowden sold 2,502 shares of the business's stock in a transaction on Thursday, June 17th. The shares were sold at an average price of $60.02, for a transaction totalling $150,170.04. Following the completion of the sale, the insider now directly owns 17,989 shares of the company's stock, valued at $1,079,699.78. Learn More on Christopher Bowden's trading history.
Who are Agios Pharmaceuticals' active insiders?
Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company.
Learn More about insider trades at Agios Pharmaceuticals. Information on this page was last updated on 12/11/2024.
